UniQure's experimental gene therapy has shown sustained Factor IX activity in a Phase II study assessing its potential to treat haemophilia B.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.